RU2002124599A - Фармацевтическая композиция - Google Patents
Фармацевтическая композицияInfo
- Publication number
- RU2002124599A RU2002124599A RU2002124599/15A RU2002124599A RU2002124599A RU 2002124599 A RU2002124599 A RU 2002124599A RU 2002124599/15 A RU2002124599/15 A RU 2002124599/15A RU 2002124599 A RU2002124599 A RU 2002124599A RU 2002124599 A RU2002124599 A RU 2002124599A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- pyrimidinyl
- phenylethanesulfonamide
- methoxyphenoxy
- methoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 17
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- HKVAMTJHUNKYQI-UHFFFAOYSA-N n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-2-phenylethanesulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OC)=C1NS(=O)(=O)CCC1=CC=CC=C1 HKVAMTJHUNKYQI-UHFFFAOYSA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000002045 Endothelin Human genes 0.000 claims 2
- 108050009340 Endothelin Proteins 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Фармацевтическая композиция для уменьшения боли при эндотелин-индуцированном заболевании, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
2. Фармацевтическая композиция по п.1, где эндотелин-индуцированным заболеванием является рак простаты.
3. Фармацевтическая композиция для облегчения остеогенных заболеваний, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
4. Фармацевтическая композиция для уменьшения боли, сопровождающей остеогенез, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
5. Фармацевтическая композиция для уменьшения боли, сопровождающей костные метастазы при раке простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
6. Фармацевтическая композиция для облегчения остеогенных заболеваний, связанных с костными метастазами при раке простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
7. Фармацевтическая композиция для подавления роста раковых клеток рака простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
8. Фармацевтическая композиция для подавления роста раковых клеток по п.1, где рак простаты является гормононезависимым раком простаты.
9. Фармацевтическая композиция для подавления прогрессии рака простаты, причем эта фармацевтическая композиция содержит N-[6-метокси-5-(2-метоксифенокси)-2-(2-пиримидинил)-4-пиримидинил]-2-фенилэтенсульфонамид или его фармацевтически приемлемую соль в качестве эффективного компонента.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000037314 | 2000-02-16 | ||
| JP2000037313 | 2000-02-16 | ||
| JP2000-37314 | 2000-02-16 | ||
| JP2000-37313 | 2000-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002124599A true RU2002124599A (ru) | 2004-03-10 |
Family
ID=26585418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002124599/15A RU2002124599A (ru) | 2000-02-16 | 2000-10-27 | Фармацевтическая композиция |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6774131B1 (ru) |
| EP (1) | EP1256344B1 (ru) |
| JP (2) | JP3832229B2 (ru) |
| KR (1) | KR20020075797A (ru) |
| CN (1) | CN1434715A (ru) |
| AR (1) | AR031679A1 (ru) |
| AT (1) | ATE348617T1 (ru) |
| AU (1) | AU2000279614A1 (ru) |
| BR (1) | BR0017120A (ru) |
| CA (1) | CA2395711A1 (ru) |
| DE (1) | DE60032517T2 (ru) |
| ES (1) | ES2277856T3 (ru) |
| HU (1) | HUP0204139A3 (ru) |
| RU (1) | RU2002124599A (ru) |
| WO (1) | WO2001060370A1 (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| EP2114418A4 (en) * | 2007-02-09 | 2013-01-09 | Poniard Pharmaceuticals Inc | ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| WO2009099651A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
| WO2009141167A1 (en) * | 2008-05-23 | 2009-11-26 | Synthon B.V. | Bosentan salts |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| HK1213946A1 (zh) | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102580C (zh) * | 1995-12-20 | 2003-03-05 | 山之内制药株式会社 | 芳基乙烯基磺酰胺衍生物及其医药组合物 |
| US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
| US6673832B1 (en) * | 1998-05-04 | 2004-01-06 | Gudarz Davar | Methods for identifying compounds for treating pain |
-
2000
- 2000-10-27 EP EP00970160A patent/EP1256344B1/en not_active Expired - Lifetime
- 2000-10-27 RU RU2002124599/15A patent/RU2002124599A/ru not_active Application Discontinuation
- 2000-10-27 ES ES00970160T patent/ES2277856T3/es not_active Expired - Lifetime
- 2000-10-27 CA CA002395711A patent/CA2395711A1/en not_active Abandoned
- 2000-10-27 JP JP2000328374A patent/JP3832229B2/ja not_active Expired - Fee Related
- 2000-10-27 AU AU2000279614A patent/AU2000279614A1/en not_active Abandoned
- 2000-10-27 WO PCT/JP2000/007573 patent/WO2001060370A1/ja not_active Ceased
- 2000-10-27 AT AT00970160T patent/ATE348617T1/de not_active IP Right Cessation
- 2000-10-27 DE DE60032517T patent/DE60032517T2/de not_active Expired - Fee Related
- 2000-10-27 KR KR1020027010589A patent/KR20020075797A/ko not_active Withdrawn
- 2000-10-27 BR BR0017120-4A patent/BR0017120A/pt not_active IP Right Cessation
- 2000-10-27 AR ARP000105669A patent/AR031679A1/es not_active Application Discontinuation
- 2000-10-27 US US10/181,489 patent/US6774131B1/en not_active Expired - Fee Related
- 2000-10-27 CN CN00818938A patent/CN1434715A/zh active Pending
- 2000-10-27 HU HU0204139A patent/HUP0204139A3/hu active IP Right Revival
-
2006
- 2006-03-29 JP JP2006090667A patent/JP2006176542A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001302514A (ja) | 2001-10-31 |
| CA2395711A1 (en) | 2002-07-18 |
| EP1256344A4 (en) | 2004-12-29 |
| HUP0204139A2 (en) | 2003-05-28 |
| CN1434715A (zh) | 2003-08-06 |
| ATE348617T1 (de) | 2007-01-15 |
| WO2001060370A1 (en) | 2001-08-23 |
| DE60032517D1 (de) | 2007-02-01 |
| EP1256344B1 (en) | 2006-12-20 |
| AR031679A1 (es) | 2003-10-01 |
| EP1256344A1 (en) | 2002-11-13 |
| US6774131B1 (en) | 2004-08-10 |
| HUP0204139A3 (en) | 2003-07-28 |
| ES2277856T3 (es) | 2007-08-01 |
| AU2000279614A1 (en) | 2001-08-27 |
| BR0017120A (pt) | 2003-01-14 |
| JP3832229B2 (ja) | 2006-10-11 |
| KR20020075797A (ko) | 2002-10-05 |
| JP2006176542A (ja) | 2006-07-06 |
| DE60032517T2 (de) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002124599A (ru) | Фармацевтическая композиция | |
| RU2463302C2 (ru) | Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| LU92602I2 (fr) | Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| SG166827A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| CA2349142A1 (en) | Compositions and methods for stimulating gastrointestinal motility | |
| WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
| DE60020825D1 (de) | Pharmazeutische zusammensetzungen die dipeptidylpeptidase iv inhibitoren enthalten zur förderung des wachstums | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| YU6602A (sh) | Pirimidin-2,4,6-trion metaloproteinazni inhibitori | |
| NO20031852D0 (no) | Pyrimidin-2,4,6-trion metalloproteinase inhibitorer | |
| WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2002020466B1 (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| NO20062098L (no) | Faststofftilstandmontelukast | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| CA2263203A1 (en) | 3,6-ketal and enol ether macrolide antibiotics | |
| CA2607098A1 (en) | Dispersible bosentan tablet | |
| PL365054A1 (en) | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | |
| BRPI0411085A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv | |
| RU2002118304A (ru) | Способ подавления чувства страха | |
| ATE389655T1 (de) | Pyrimidinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050322 |